Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
| Revenue | ||||
| Total revenue | $ 2,082,553 | $ 3,064,379 | $ 6,973,109 | $ 10,799,135 |
| Cost of revenue | 974,711 | 1,476,787 | 2,988,688 | 4,175,056 |
| Gross profit | 1,107,842 | 1,587,592 | 3,984,421 | 6,624,079 |
| Operating expenses | ||||
| Product development | 649,070 | 959,186 | 2,153,834 | 3,950,305 |
| Sales and marketing | 566,147 | 954,759 | 1,977,996 | 4,984,983 |
| General and administrative | 1,401,101 | 1,830,663 | 4,458,949 | 6,409,564 |
| Depreciation and amortization | 176,715 | 1,551,480 | 746,966 | 4,475,485 |
| Impairment of long-lived assets | 892,103 | 892,103 | 30,562,944 | |
| Total operating expenses | 3,685,136 | 5,296,088 | 10,249,849 | 50,383,281 |
| Loss from operations | (2,577,294) | (3,708,496) | (6,265,427) | (43,759,202) |
| Other (expense) income | ||||
| Interest (expense) income, net | (202,644) | (395,422) | (917,015) | (609,150) |
| Change in fair value of convertible notes | 185,000 | (1.113000) | (863,457) | (2,840,000) |
| Change in fair value of derivative liability | 2,256 | 54,153 | ||
| Other expense, net | 9,781 | |||
| Total other (expense) income | (17,644) | (1,506,166) | (1,770,691) | (3,394,997) |
| Net loss from continuing operations before income taxes | (2,594,938) | (5,214,662) | (8,036,118) | (47,154,199) |
| Income tax benefit on continuing operations | 40,666 | 268,152 | ||
| Net loss from continuing operations | (2,594,938) | (5,173,996) | (8,036,118) | (46,886,047) |
| Net gain (loss) from discontinued operations | 2,869,908 | (115,398) | (6,936,881) | |
| Net loss | $ (2,594,938) | $ (2,304,088) | $ (8,151,516) | $ (53,822,928) |
| Basic weighted average common shares outstanding (in Shares) | 8,195,393 | 3,883,847 | 6,486,669 | 2,421,262 |
| Basic loss per common share from continuing operations (in Dollars per share) | $ (0.32) | $ (1.33) | $ (1.24) | $ (19.36) |
| Basic earnings (loss) per common share from discontinued operations (in Dollars per share) | 0.74 | (0.02) | (2.87) | |
| Basic loss per common share (in Dollars per share) | $ (0.32) | $ (0.59) | $ (1.26) | $ (22.23) |
| Software | ||||
| Revenue | ||||
| Total revenue | $ 2,069,845 | $ 2,980,926 | $ 6,909,399 | $ 10,150,011 |
| Consulting | ||||
| Revenue | ||||
| Total revenue | 6,200 | 76,500 | 46,000 | 618,809 |
| Other revenue | ||||
| Revenue | ||||
| Total revenue | $ 6,508 | $ 6,953 | $ 17,710 | $ 30,315 |
| X | ||||||||||
- Definition Amount of increase (decrease) in the fair value of convertible notes recognized in the income statement. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of nonoperating interest income (expense). No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|